| Dr Adrian H Flores, MD | |
|
275 W Macarthur, Oakland, CA 94611-5641 | |
| (510) 752-1000 | |
| Not Available |
| Full Name | Dr Adrian H Flores |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 275 W Macarthur, Oakland, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568790137 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A 115311 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366417420 PECOS PAC ID: 5496668410 Enrollment ID: O20031112000551 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Entity Name | San Francisco Emergency Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134110661 PECOS PAC ID: 5698662518 Enrollment ID: O20040303001130 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Entity Name | Chase Dennis Emergency Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033152350 PECOS PAC ID: 2264345172 Enrollment ID: O20041109001017 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adrian H Flores, MD 275 W Macarthur, Oakland, CA 94611-5641 Ph: (510) 752-1000 | Dr Adrian H Flores, MD 275 W Macarthur, Oakland, CA 94611-5641 Ph: (510) 752-1000 |
News Archive
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.
In the rancorous public debate over federal research funding, stem cells are generally assigned to one of two categories: embryonic or adult.
The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.
Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.
The novel coronavirus COVID-19 is rapidly spreading around the globe, infecting more than 90,000 and killing more than 3,000 people. Now, an epidemiologist says it may eventually threaten about 70 percent of the total population.
› Verified 2 days ago
Daniel Mantuani, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1506 4th Ave Apt 5, Apt 5, Oakland, CA 94606 Phone: 504-390-5474 | |
Jennifer I. Harris, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
Benjamin J. Bonnes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 | |
Richard J. Knight, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 275 W Macarthur Blvd, Oakland, CA 94611 Phone: 510-752-1000 | |
Michael S. Gelfond, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
Dr. Kayla Enriquez, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1411 E 31st St, Oakland, CA 94602 Phone: 510-437-4564 | |
Dr. Emily Meilan Sze, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 Hawthorne Ave, Oakland, CA 94609 Phone: 510-869-2500 |